PSCA Chimeric Antigen Receptor (CAR): A Comprehensive Guide and Our Service & Product Introduction

PSCA represents a uniquely valuable target for solid tumor immunotherapy, with strong clinical validation and a rapidly evolving research landscape. The lack of standardized, high-quality PSCA CAR expression vectors remains a major bottleneck for researchers worldwide-and our comprehensive vector portfolio and custom services are designed to solve this critical challenge.

Whether you are conducting basic preclinical research, optimizing CAR-T constructs, or advancing early-stage therapeutic development, RGBiotech’s PSCA CAR plasmids provide the reliability, flexibility, and performance you need to accelerate your research and drive breakthroughs in solid tumor immunotherapy. Contact us today to learn more about our catalog products, custom solutions, and technical support for your PSCA CAR research projects. For custom vector quotes, product specifications, or technical support, please reach out to us at admin@rgbiotech.com. We support global shipping and provide full documentation for academic and industrial research use.

Our PSCA CAR Expression Plasmid Vector Products and Custom Services

To empower global researchers and biotech teams to advance PSCA-targeted immunotherapy, RGBiotech offers a comprehensive lineup of PSCA CAR expression plasmids covering differenct CAR generations, plus flexible custom vector construction services tailored to unique research needs. Our vectors are engineered for high expression efficiency, reliable T cell engineering, and strict quality control-ideal for preclinical research, drug discovery, and early-stage clinical development.

RGBiotech provides validated PSCA CAR plasmids for 1st, 2nd, 3rd, 4th, and 5th-generation designs, with pre-optimized co-stimulatory domains (CD28, 4-1BB, OX40, ICOS) and signaling modules to match every research goal-from basic mechanistic studies to advanced armored CAR development.

Our portfolio includes multiple backbone systems to support diverse immune cell engineering platforms.
1) Lentiviral Vectors: Production of lentiviral particles, high transduction efficiency for primary T cells, NK cells, and hematopoietic stem cells; ideal for stable CAR expression;
2) Retroviral Vectors: Production of retroviral particles, stable integration, high expression in T lymphocytes; suitable for traditional CAR-T manufacturing;
3) AAV Vectors: Production of AAV particles, low immunogenicity, non-integrating; safe for in vivo and ex vivo gene delivery;
4) Non-Viral (Plasmid DNA) Vectors: Transposon-based (e.g., Sleeping Beauty, PiggyBac) and conventional eukaryotic expression vectors; cost-effective, safe, and scalable for non-viral T cell engineering.

Product Features

Product Advantages of Our PSCA CAR Vectors

Custom PSCA CAR Vector Construction Service

Beyond our standard catalog, we offer bespoke PSCA CAR vector design and construction to meet unique research requirements: custom scFv sequences, personalized co-stimulatory domain combinations, dual-targeting CAR designs, cytokine-secreting armored CARs, and specialized promoter/selection marker modifications. Our team of molecular biology experts ensures fast turnaround times, strict quality assurance, and full technical support throughout the project.

Product Applications

Introduction of PSCA

Prostate Stem Cell Antigen (PSCA) is a highly conserved, cell surface-associated glycoprotein-encoding gene, first identified and cloned in 1998 as a gene significantly upregulated in human prostate cancer xenograft models. The human PSCA gene is located on the long arm of chromosome 8 (8q24.2), spanning a compact genomic region with a canonical open reading frame that encodes two main protein isoforms (123 amino acids and 114 amino acids) due to natural start codon polymorphism. Classified as a member of the Thy-1/Ly-6 protein family, PSCA shares low but distinct homology with lymphocyte stem cell antigen 2 (SCA-2), highlighting its unique role in epithelial cell biology and tumor progression.

PSCA is a glycosylphosphatidylinositol (GPI)-anchored cell membrane glycoprotein, a structural feature that anchors it tightly to the outer leaflet of the plasma membrane, specifically within lipid raft microdomains enriched in glycosphingolipids and cholesterol. The mature protein undergoes post-translational glycosylation and GPI modification, forming a compact, extracellularly oriented structure with no cytoplasmic or transmembrane domains in its native form. This unique membrane localization makes PSCA an ideal extracellular target for monoclonal antibodies, CAR-T cells, and other targeted therapeutic modalities, as it is readily accessible to immune effector cells and therapeutic agents without requiring intracellular internalization for activity.

Under normal physiological conditions, PSCA exhibits strict tissue specificity and low baseline expression, a key characteristic that drives its value as a cancer therapeutic target. It is predominantly expressed in the basal epithelial, secretory, and neuroendocrine cells of the normal prostate gland, with minimal low-level expression detected in the bladder urothelium, gastric mucosa, placenta, colon, kidney, and small intestine. Physiologically, PSCA is implicated in the regulation of epithelial cell proliferation, cell cycle progression, cell-cell adhesion, and mild signal transduction pathways, with no critical role in vital organ function-minimizing off-target toxicity risks in targeted therapy.

PSCA is one of the most well-validated tumor-associated antigens (TAAs) for solid tumors, characterized by dramatic upregulation in malignant tissues while maintaining low expression in healthy organs. It is highly overexpressed in: 1) Prostate Cancer: Over 80% of primary prostate cancers and nearly 100% of metastatic castration-resistant prostate cancer (mCRPC) show high PSCA expression, with expression levels correlating directly with tumor stage, Gleason score, invasiveness, and poor patient prognosis. 2) Bladder Cancer: Strongly expressed in transitional cell carcinoma, particularly in high-grade and metastatic disease, serving as a prognostic biomarker and therapeutic target. 3) Pancreatic Cancer & Gastric Cancer: Significant overexpression in adenocarcinoma subtypes, linked to tumor progression and treatment resistance. This "low normal, high tumor" expression profile positions PSCA as a top-tier target for solid tumor immunotherapy, addressing a critical unmet need in CAR-T development for non-hematological malignancies.

Introduction of PSCA Chimeric Antigen Receptor (CAR)

PSCA CAR is a genetically engineered chimeric antigen receptor designed to redirect T lymphocytes (and other immune effector cells) to specifically recognize and kill PSCA-positive tumor cells. Structurally, a classic PSCA CAR construct consists of four core modular domains: an extracellularPSCA-specific single-chain variable fragment (scFv) (derived from high-affinity anti-PSCA monoclonal antibodies), a hinge/transmembrane domain for membrane anchoring, one or more intracellular co-stimulatory domains, and a CD3ζ signaling domain that triggers T cell activation and cytotoxicity.

PSCA CAR technology has evolved rapidly across multiple generations, each optimized to enhance T cell persistence, cytotoxicity, and safety-mirroring the broader advancement of CAR-T engineering.
1) First-Generation PSCA CAR: Contains only CD3ζ intracellular signaling domain, no co-stimulation; limited T cell activation, short persistence, minimal anti-tumor efficacy in solid tumors.
2) Second-Generation PSCA CAR: Integrates one co-stimulatory domain (most commonly 4-1BB/CD137 or CD28) with CD3ζ; significantly improves T cell proliferation, survival, and cytotoxicity; the most widely used generation in preclinical and early clinical studies.
3) Third-Generation PSCA CAR: Combines two co-stimulatory domains (e.g., CD28 + 4-1BB, CD28 + OX40) to further boost signaling strength and T cell persistence; enhanced efficacy in solid tumor models with high tumor microenvironment (TME) suppression.
4) Fourth-Generation (Armored) PSCA CAR: Engineered to secrete cytokines (e.g., IL-12, IL-15), checkpoint inhibitors (anti-PD-L1), or chemokines to remodel the TME, overcome immunosuppression, and recruit endogenous immune cells.
5) Fifth-Generation PSCA CAR: Next-generation design with integrated cytokine receptor signaling, dual-targeting motifs, or safety switch systems (e.g., inducible caspase-9) for enhanced efficacy, controllability, and safety; focused on solid tumor-specific challenges.

Key Research Findings & Clinical Progress

Preclinical studies in xenograft and syngeneic mouse models of mCRPC, bladder cancer, and pancreatic cancer demonstrate that second- and third-generation PSCA CAR-T cells effectively infiltrate solid tumors, induce robust tumor regression, and prolong survival without severe off-target toxicity to normal PSCA-expressing organs. Combination strategies (PSCA CAR-T + radiotherapy, chemotherapy, or immune checkpoint inhibitors) show synergistic anti-tumor effects, overcoming TME-mediated resistance. Dual-targeting PSCA CAR-T (e.g., PSCA + PSMA, PSCA + MUC1) reduces tumor antigen escape and improves treatment durability.

As of 2026, multiple PSCA CAR-T cell therapies are in active clinical development, with no fully marketed (FDA/EMA approved) drugs yet-representing a high-growth, high-potential field with significant unmet demand for reliable research tools. Key clinical assets include: 1) BPX-601 (Bellicum Pharmaceuticals): First-generation PSCA CAR-T with pharmacological activation (rimiducid-inducible), in Phase 1 dose-escalation trials for mCRPC and pancreatic cancer. 2) City of Hope PSCA CAR-T: Second-generation 4-1BB-based PSCA CAR-T, Phase 1 first-in-human trial showing promising safety and preliminary efficacy in mCRPC. 3) Multiple academic and biotech-led Phase 1/2 trials (NCT05805371, NCT04045371) evaluating PSCA CAR-T alone or in combination with lymphodepletion and radiation for PSCA-positive solid tumors.

Research Hotspots & Current Challenges

Current Research Challenges

References

Contact Us